Background The genetic alterations responsible for an adverse outcome in most patients
with acute myeloid leukemia (AML) are unknown. Methods Using massively parallel DNA …

Most patients with acute myeloid leukaemia (AML) die from progressive disease after relapse,
which is associated with clonal evolution at the cytogenetic level 1 , 2 . To determine the …

Most mutations in cancer genomes are thought to be acquired after the initiating event,
which may cause genomic instability and drive clonal evolution. However, for acute myeloid …

The Cancer Genome Atlas (TCGA) has used the latest sequencing and analysis methods to
identify somatic variants across thousands of tumours. Here we present data and analytical …

Several genetic alterations characteristic of leukemia and lymphoma have been detected in
the blood of individuals without apparent hematological malignancies. The Cancer Genome …

This review will be devoted to a description of selectively fluorinated biologically active
molecules. Selective fluorination has been an extremely effective tool for modifying reactivity. …

Prostaglandin J 2 (PGJ 2 ) and its metabolites Δ 12 -PGJ 2 and 15-deoxy-Δ 12,14 -PGJ 2 (15d-PGJ
2 ) are naturally occurring derivatives of prostaglandin D 2 that have been suggested …

The peroxisome proliferator-activated receptor-γ (PPAR-γ) is a ligand-dependent nuclear
receptor that has been implicated in the modulation of critical aspects of development and …

Background The molecular determinants of clinical responses to decitabine therapy in
patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) are unclear. …

Therapy-related acute myeloid leukaemia (t-AML) and therapy-related myelodysplastic
syndrome (t-MDS) are well-recognized complications of cytotoxic chemotherapy and/or …